Cerevel Therapeutics Holdings - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CERE Nasdaq 8731 https://www.cerevel.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cerevel Therapeutics Holdings

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023 - Feb 1st, 2023 11:30 am
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update - Jan 9th, 2023 11:30 am
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 11:30 am
Are Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Investors Paying Above The Intrinsic Value? - Dec 31st, 2022 12:55 pm
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial - Dec 19th, 2022 11:30 am
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia - Dec 15th, 2022 11:30 pm
Cerevel Therapeutics to Present at Upcoming Investor Conferences - Nov 11th, 2022 11:30 am
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates - Nov 8th, 2022 11:30 am
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022 - Oct 19th, 2022 10:30 am
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference - Sep 6th, 2022 10:30 am
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes - Aug 12th, 2022 10:00 am
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock - Aug 12th, 2022 10:00 am
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock - Aug 10th, 2022 8:01 pm
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes - Aug 10th, 2022 8:01 pm
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates - Aug 1st, 2022 10:15 am
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022 - Jul 25th, 2022 9:00 pm
Cerevel Therapeutics Announces Updates to its Board of Directors - Jun 15th, 2022 10:30 am
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference - May 25th, 2022 10:30 am
Here's Why We're Not Too Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Situation - May 11th, 2022 11:38 am
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates - May 10th, 2022 10:30 am